What It Is

SLU-PP-332 is a small-molecule research compound that activates ERRα, ERRβ, and ERRγ — nuclear receptors involved in regulating energy metabolism, mitochondrial function, and oxidative metabolism. Because of these effects in preclinical studies, it is often referred to as an “exercise mimetic.”

Unlike stimulant-based compounds, SLU-PP-332 is studied for its ability to enhance the body’s natural metabolic pathways responsible for energy production and endurance — current research explores effects on mitochondrial function, fat oxidation, endurance capacity, and metabolic flexibility.

Who May Benefit

• Body recomposition research
• Endurance performance research
• Mitochondrial optimization research
• Metabolic health studies
• Research complementing structured endurance or resistance training

What to Expect

As an ERR-pathway compound rather than a stimulant, effects are researched through metabolic and mitochondrial markers (fat oxidation, endurance capacity, cellular energy production) rather than an immediate subjective stimulant effect.

It is frequently studied alongside other metabolic and mitochondrial compounds rather than as a standalone intervention.

What to Pair It With

Reconstitution

Suggested Research Dosing Strategy

Administration Notes

Sublingual administration — allow the tablet to dissolve fully under the tongue for research consistency.

No reconstitution required.

Research Considerations

SLU-PP-332’s ERR-pathway mechanism is distinct from every other compound in this category — it does not act on GLP-1, GIP, glucagon, or amylin receptors, but instead on nuclear receptors regulating mitochondrial biogenesis and oxidative metabolism directly.

This is a genuinely emerging research compound; source material frames it as one of the more exciting areas of metabolic research specifically because of this novel mechanism, though it should be treated with the caution appropriate to any early-stage research compound.